In plain terms

The claim being assessed: Persistent mTOR hyperactivation is the central rate-limiting integrator of organismal aging, and reducing mTOR activity is the dominant mechanism for extending lifespan and healthspan.

Where the evidence stands: Γ — Plausible mechanism. There is a believable biological story and partial support, but the causal step has not been demonstrated.

What this mechanism does: This makes the process worse or keeps it going, but something else starts it.

Strongest evidence for it: The preregistered primary-subclaim gate is SC2, yielding Γ. The strong experimental-benefit sensitivity is Η. A weaker primacy score must not erase the cross-species causal modulation evidence or be interpreted as refuting mTOR biology.

What decisive evidence would look like

In plain terms, researchers would change the proposed cause, confirm it changed as intended, and measure a meaningful health outcome while checking other explanations. The result should be able to support or count against the claim.

Relative explanatory fit: Alternative ranked ahead

What this review means for MTOR Hyperactivation as Aging Driver

Claim being assessed: Persistent mTOR hyperactivation is the central rate-limiting integrator of organismal aging, and reducing mTOR activity is the dominant mechanism for extending lifespan and healthspan.. This review asks whether the proposed factor causes the health outcome—not just whether the two appear together. For the wording assessed here, the evidence is rated Plausible mechanism (HSEF Γ; Moderate confidence). There is a believable biological story and partial support, but the causal step has not been demonstrated. That rating applies to this claim and scope; it does not mean the biological process is irrelevant in every setting.

Implications for health and treatment: This is an assessment of a causal explanation, not proof that a particular supplement, diet, test, or treatment improves health. A treatment claim needs studies that test the intervention in people and measure meaningful benefits and harms. These findings can help frame research and informed clinical questions, but they do not identify what is right for one person.

Limits for individual care: Evidence from cells, animals, associations, or a plausible mechanism may not predict what happens in people. The grade is limited to the exact claim, outcomes, and sources reviewed, and it is not a diagnosis or an individual forecast. Do not start, stop, or change care based on this page; discuss personal decisions with a qualified clinician.

Medical information notice: This review provides general health information, not medical advice. It cannot diagnose a condition or replace an individual discussion with a qualified clinician.

This assessment rests on 59 sources and 62 individually checked claims. 62 of those claims were verified against the original paper.

A low grade is not an accusation. It means the causal work has not been done yet, which is the ordinary state of most actively studied mechanisms in biology.

At a glance

Sub-claims assessed separately

ID	Sub-claim	Type	Level	Pivotal card
SC1	Reducing mTOR signalling extends lifespan or healthspan across experimentally assessed species.	application	Η	Card ↗
SC2	mTOR is the central rate-limiting integrator of organismal aging rather than one of several causal modulators.	primacy	Γ	Card ↗

Visual Evidence Cards · Pivotal Subclaims

Pivotal subclaim illustrations

Dark-theme simulated-micrograph renders and concise causal evidence summaries for the pivotal subclaims that govern this review's grade. Click any card to inspect the master 2400×2400 render.

Master 2400×2400 render ↗

Master 2400×2400 render ↗

Figures

Explanatory figures summarizing this review. They carry no evidential weight of their own; where a figure and the review differ, the review governs.

Full assessment

From here the review is written for a technical reader: caps and thresholds, competing models, the independence basis, and the citation ledger.

Sources: 59 primary reports; claims: 62; verified: 62; unverified: 0. Verification is bounded attribution. Access: 4 partial-body and 55 complete abstract/status examinations. Cutoff: 2026-10-05. No complete-paper audit or blinded calibration claimed. Adversarial review: Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-06. 0 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: Approved as revised.

AT A GLANCE

mTORC1 is a conserved causal modulator of experimental lifespan; central rate-limiting primacy and human healthy-life extension remain unproved.

Deciding experiment: Independent-site factorial normal-aging mammalian trial of adult mTORC1 normalization, drug-resistant target rescue and orthogonal MEK/damage interventions, stratified by tissue activation measured before treatment.

Belief versus evidence: The preregistered primary-subclaim gate is SC2, yielding Γ. The strong experimental-benefit sensitivity is Η. A weaker primacy score must not erase the cross-species causal modulation evidence or be interpreted as refuting mTOR biology.

Best-supported rival: Multifactorial nutrient-sensitive network. Adult selective normalization of measured excess mTORC1, with a drug-resistant rescue and independently engaged comparator pathways, distinguishes one potent node from a necessary rate-limiting bottleneck.

COMPETING MECHANISTIC MODELS

Rank 1: Multifactorial nutrient-sensitive network (Η). mTORC1 is one potent controllable node with interacting parallel processes. Convergent genetics and drug survival effects, combined MEK benefit and tissue-specific responses. Additivity alone does not establish fully independent pathways.

Rank 2: Pleiotropic nutrient sensing (Ζ). Autophagy translation immune and metabolic effects jointly influence outcomes. Epistasis and mediator perturbations support defined branches. No single mediator is shown necessary across all organisms and endpoints.

Rank 3: Disease and immune protection (Ε). Cancer delay and organ-specific protection explain part of survival benefit. Tumour-prone and clinical immune studies show relevant disease effects. This alone does not explain all non-neoplastic functional benefits.

Rank 4: ROS and damage mediation (Γ). mTOR changes survival partly through oxidative damage and proteostasis. Liver marker changes and autophagy contrasts are compatible. Marker changes do not establish survival mediation.

Rank 5: Central hyperfunction bottleneck (Γ). Persistent mTOR hyperactivation is the dominant autonomous aging integrator. Strong intervention potency and cellular geroconversion favor this possibility. Heterogeneous signaling and contextual inhibition harms leave central primacy unproved.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

FULL REVIEW

Registered claim and scope

Persistent mTOR hyperactivation is the central rate-limiting integrator of organismal aging, and reducing mTOR activity is the dominant mechanism for extending lifespan and healthspan.

Use the index primary-subclaim rule with SC2 as the explicit central-driver gate. SC1 lifespan benefit is not substituted for SC2 primacy. Normal aging is distinguished from developmental slowing, cancer suppression and treatment of selected diseases.

Selection: public-interest rank 13 from the editorial ranking compiled 2026-09-23; categorical prior verdicts were visible. Private fresh review; earlier documents are preserved.

Evidence and causal interpretation

Genetic TOR/TSC/S6K and adult rapamycin results converge on lifespan modulation across model systems. The heterogeneous-mouse late-life result removes a purely developmental explanation. Original dose-study Results confirm pooled three-site effects, sex-dependent exposure and variable lower-dose site responses; slope estimates are explicitly uncertain. These support potency, not a unique aging bottleneck [1,30,31,42,44–47,55,57].

Physiology maps countercontexts. Age-related mTOR activity is not uniformly elevated; Terc-null and GHRKO animals can lose survival under inhibition, and endothelial or cardiac TORC2 signaling can be protective. These are bounded counterexamples to monotonic pan-mTOR models, not refutations of normal mouse benefit [2,5,6,20,22,23,25,51].

The intervention affects several downstream systems. Autophagy, splicing, energy metabolism, secretory programs and translation have defined mechanistic evidence. Selected biomarkers do not establish lifespan mediation. Original 2025 mouse combination Results show additive survival benefit with MEK targeting and explicitly acknowledge reused liver pathology and incomplete longitudinal tumor-arm coverage [3,9,10,36,37,44,53,57,59].

The human evidence separates immune modulation from healthy-life extension. RTB101 phase2b first combination comparison was null; a second prespecified pooled single-dose comparison was positive. Phase3 used a different population and symptomatic endpoint and was null despite antiviral transcriptional engagement. Original PEARL Methods/Results show 114 completers and 11 excluded discontinuations, lower compounded exposure, a null primary visceral-fat endpoint, secondary female lean-mass signal and exploratory survey analyses. None tests general human healthy lifespan [14,17,49,54,58].

HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

Subclaim matrix and aggregation

Preregistered aggregation: primary-subclaim. The preregistered primary-subclaim gate is SC2, yielding Γ. The strong experimental-benefit sensitivity is Η. A weaker primacy score must not erase the cross-species causal modulation evidence or be interpreted as refuting mTOR biology. Sensitivities: weakest-link Γ; primary-subclaim Γ; scope-matched Γ.

Decisive-perturbation inventory and causal tally

[1] Late-life rapamycin extends survival at three sites Does not isolate aging rate from disease delay or prove primacy

[2] Rapamycin and S6K loss shorten survival in Terc-null context Does not negate normal mouse benefit

[3] IL1A translation mediates a defined SASP effect with rescue Does not establish organismal aging mediation; linked erratum unexamined

[4] Muscle mTORC1 activation and inhibition alter sarcopenic phenotypes Does not establish all-organ rate limitation

[5] Age-related signaling is heterogeneous rather than uniformly elevated Does not exclude transient or cell-specific hyperactivation

[6] Reduced endothelial mTOR disrupts aged hematopoietic support Does not generalize all tissues

[7] Late short rapamycin improves cardiac function Does not demonstrate whole-life or human benefit

[8] Multiple pathway drugs combine for lifespan benefit Does not prove complete pathway independence

[10] Autophagy and energetics change with distinct timing during functional benefit Does not isolate one necessary universal mediator

[12] Rapamycin preserves selected aged tendon mechanics Does not show all functional domains

[13] RAD001 affects selected renal and other tissue pathology Does not establish lifespan or centrality

[14] Primary visceral-fat endpoint is null; selected secondary female lean-mass signal Completer analysis and broad exploratory outcomes do not prove human healthy-life extension

[15] Rapamycin impairs glucose handling and islet measures Does not negate survival benefit or establish all dosing schedules harmful

[16] Cholesterol-axis mTORC1 activation contributes to engineered aging phenotypes Rescue of an engineered lesion is not proof of normal-aging primacy

[17] Low-dose everolimus improves vaccination response Does not measure healthy lifespan

[18] Isoleucine restriction improves frailty and survival with sex dependence Diet has multiple mediators; no exclusive mTOR mechanism

[19] Drug combinations engage distinct network and lipid mechanisms Does not establish human benefit or independent pathways in mammals

[20] TORC2 survival effects reverse with food context and intake Does not imply universal TORC2 inhibition benefit

[23] Rapamycin extends control life but shortens GHRKO life with mTORC2 suppression Context boundary does not negate normal-aging rapamycin effects

[24] Multiple age-sensitive phenotypes improve while cataract and testis harms rise Does not establish uniform aging-rate suppression

[25] Sex hormone and tissue perturbations uncouple metabolic health from survival Does not establish universal effects outside mapped contexts

[26] Cardiac TORC2 activation improves autophagy function and survival Does not resolve all organismal TORC2 effects

[27] Diet and rapamycin share TOR suppression yet differ physiologically Does not quantify distinct lifespan mediators

[28] Late rapamycin improves survival and selected functions Many metabolic and activity measures do not change

[29] Metabolic effects vary with treatment duration Does not directly establish survival mediation

[30] ARGK1 is a defined effector of S6K longevity with AMPK link Does not show a universal mammalian mediator

[31] Dose and sex gradients replicate survival effects Gompertz slope estimates do not prove slowed demographic aging rate

[32] Short rapamycin improves bone inflammation and microbiome measures Does not demonstrate systemic lifespan mediation

[34] Functional benefits persist after drug withdrawal Does not establish whole-body or human persistence

[35] Lifespan growth and fitness tradeoffs depend on sex and exposure timing Does not generalize all ages or species

[37] SFA1 is required for selected TOR and diet longevity effects Not a universal mediator; linked erratum content unexamined

[38] Weekly rapamycin improves survival to planned sacrifice Disease context and censored follow-up are not natural maximum lifespan

[39] BCAA restriction has sex-specific survival and frailty effects Does not isolate mTOR as dominant diet mediator

[40] Rapatar delays cancer and increases survival Does not distinguish general aging from engineered cancer rescue

[41] mTOR reactivation influences senescence in arrested cells In vitro geroconversion is not organismal aging primacy

[42] Late dose and intermittent regimens affect survival by sex Food-source variation complicates comparisons; shared ITP platform

[43] Rapamycin fails to rescue defective HSC function despite fibroblast benefit Not a normal-aging human trial

[44] Autophagy loss blocks selected longevity pathways Shared downstream requirement does not establish mTOR exclusivity

[45] TOR and Sch9 deletion extend replicative life with dietary epistasis Yeast replicative life is not mammalian healthspan

[46] Multiple TOR manipulations extend life depending on nutrition Does not establish uniform central rate limitation

[47] Downstream genetic perturbation extends survival and selected functions Developmental and sex boundaries remain; erratum details unexamined

[48] Aged donor HSC engraftment is preserved Shares mutant platform; no independent lifespan replication

[49] Phase2b pooled single-dose contrast positive after combination null; phase3 primary null despite IFN engagement Endpoint and population changes limit direct comparison and neither trial measures healthy lifespan

[50] Transient rapamycin changes survival with sex and tumour-spectrum boundaries Up-to-60% life expectancy is not universal full-life extension

[51] Survival improves but few age phenotypes improve; young controls reveal age-independent effects Does not negate other mouse background or function benefits

[52] DL001 separates mTORC1 inhibition from several metabolic side effects Does not report lifespan benefit

[53] MEK inhibition adds survival benefit to intermittent rapamycin with separate engagement Additivity does not prove perfect independence or preclude shared network centrality

[54] Low-dose TORC1 combination reduces reported infections and improves immune endpoints Does not establish general healthy-life extension

[55] Genetic reduction extends survival with segmental functional preservation Developmental manipulation and uneven organ effects do not prove central primacy

[56] Short low-dose rapamycin suggests selected cardiac effects Small short trial does not test lifespan

[57] Rapamycin longevity requires defined autophagy and translation pathways Does not establish the same mediator across mammals

[58] Short treatment leaves measured cognition performance and perceived health unchanged Small safety pilot cannot exclude longer-term efficacy; enrollment wording requires body verification

[59] Polyamine and hypusination perturbation tests selected fasting longevity mechanisms Human fasting markers are not human lifespan mediation; not exclusive mTOR proof

Tally: 53 discriminating contrasts. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. Shared cohorts, experimental platforms, transgenic lineages and repeated outcomes do not constitute fully independent causal lines.

Cap audit, precedence and Β/Γ/Δ boundary

Single-organ biomarkers and cell geroconversion cannot carry the primacy claim. Cross-species survival plus independent genetics allow Η for SC1 within mapped experimental contexts; broad human or universal-centrality extrapolation remains Γ. No manufactured one-species hard cap is applied to the whole corpus.

Gamma hard-rule audit: Biomarkers alone do not cross the aging-trajectory boundary. Species, strain, developmental timing and nonspecific interventions constrain the scope of each result.

SC1 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: yes. Independent TOR/S6K genetics, adult pharmacology, conserved model-system effects and replicated heterogeneous-mouse dose/site/sex survival results support the constrained experimental modulation claim. This is not a human-life claim or a claim that every function improves.

SC2 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. There is no scope-matched discriminator showing that persistent mTOR hyperactivation is the central necessary rate-limiting integrator of normal mammalian aging. Signaling heterogeneity, harmful inhibition contexts and additional benefit from MEK targeting favor a network.

Upward threshold ladder

SC1 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: yes.

SC1 Ε: “Requires causal effect in constrained contexts, backgrounds, or species.” Satisfied: yes.

SC1 Ζ: “Requires: - Reproducible intervention effects - Mechanistic narrowing - Evidence not reducible to general sickness, caloric reduction, or developmental artifacts” Satisfied: yes.

SC1 Η: “Requires: - Robust cross-context intervention evidence - Mechanistic specificity - Strong alignment of lifespan/healthspan outcomes” Satisfied: yes.

SC1 Θ: “Requires high reproducibility with minimal contextual contradiction.” Satisfied: no. A broader generalization requires independent mammalian replication with complete functional trajectories and mediator rescue; human efficacy requires prespecified durable clinical outcomes.

SC2 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. Selective adult normalization must prevent or strongly delay multisystem aging, establish necessity and timing, and occlude independently engaged alternative interventions with a credible rescue.

Upper ladder: Η is assigned to the mapped experimental modulation claim because distinct genetics, adult pharmacology and multisite replication exclude different errors. It is withheld from centrality: human genetics, clinical immune endpoints and pathway epistasis do not establish central aging necessity, sufficiency or rate limitation. Θ–Ω would require stronger convergence and scope-matched necessity evidence.

Independence: Conserved effect direction across independent methods supports SC1. ITP sites and repeated doses are replication within one coordinated platform; HSC follow-ups reuse S6K genetics. Separate human trial cohorts test specific immune endpoints and do not independently establish organismal aging mediation.

Adult late-life rapamycin [1, 31, 42]: Excludes a solely developmental explanation; shared ITP platform limits independence.

Independent genetic perturbations [47, 55, 46, 45]: Reduces drug-only explanations while retaining developmental/pleiotropic limits.

Defined mediator epistasis [57, 30, 44]: Tests selected branches rather than one universal mediator.

Comparator and contextual countertests [53, 2, 23]: Challenge monotonic or exclusive centrality.

Falsification and pitfalls

Benefit is segmental or age-independent in some traits. Neff young controls, Wu organ-specific preservation and Baar signaling heterogeneity limit uniform rate claims. Additional downgrade: False.

Additional pathway intervention retains benefit. Fly multi-drug and mouse trametinib/rapamycin additivity challenge exclusivity but do not prove perfect independence. Additional downgrade: False.

Target engagement with clinical primary null. RTB101 phase3 IFN responses persist despite null symptomatic respiratory illness. Additional downgrade: False.

Intervention efficacy substituted for causal primacy. SC1 Η is kept separate from SC2 Γ.

Lifespan equated with every healthspan domain. Metabolic harms, segmental phenotyping and tumor-spectrum shifts are retained.

mTORC1 and mTORC2 conflated. Rictor, GHRKO and endothelial countercontexts are explicit.

Provider meter treated as adjudication. Consensus prose rejects primacy while its meter favors yes; neither controls the score.

Clinical secondary signals promoted over primary null. PEARL completer analysis, formulation and subgroup limits remain visible.

Adversarial steelman: above, then below

Δ for central primacy would require a discriminator matching the central bottleneck claim; survival efficacy alone tests a weaker claim. Θ for SC1 would require still broader independent necessary-pathway convergence and less residual endpoint/context ambiguity.

Β for primacy would ignore mechanistic perturbation support, while Ε for SC1 would understate convergent genetic, adult pharmacologic and cross-species survival evidence.

Retain Γ for registered centrality and Η for experimentally mapped modulation. Prespecify human clinical efficacy as a separate claim rather than infer it from vaccine response.

Final score, causal direction and M/S/D

The preregistered primary-subclaim gate is SC2, yielding Γ. The strong experimental-benefit sensitivity is Η. A weaker primacy score must not erase the cross-species causal modulation evidence or be interpreted as refuting mTOR biology.

Perturbation and rescue demonstrate causal effects, ruling out a solely downstream correlate under steps1–2. Uniform initiation, prevention and rate limitation are not established, and universal necessity is not shown under steps3–4. Defined persistent signaling can reinforce dysfunction; step5 applies.

Momentum: Decisive work underway. The 2025 mouse combination and YTHDF1 studies and PEARL trial provide named active boundary tests; no unverified recruiting status is asserted.

Stability: Stable. No named pending result is asserted to be likely to move the registered score imminently.

Divergence: Contested; no single implied-level arithmetic. These dimensions do not change level or confidence.

PROPOSED DECISIVE EXPERIMENTS

Independent-site factorial normal-aging mammalian trial of adult mTORC1 normalization, drug-resistant target rescue and orthogonal MEK/damage interventions, stratified by tissue activation measured before treatment.

Readout: Prespecified survival and longitudinal multi-organ function, alongside target-specific signaling and time-resolved mediation. Controls: Vehicle, young controls, rescue allele, equal exposure, TORC2 monitoring, background/sex replication, tumor adjudication and blinded outcomes. Supporting: Normalization prevents multisystem decline and occludes independently engaged comparator benefits with rescue specificity. Falsifying: Additional benefits persist after complete mTOR normalization or decline proceeds despite selective engagement.

RESEARCH TIMELINE

KNOWLEDGE GAPS

Which normal-aging cell types actually develop excess mTORC1 signaling, when, and relative to injury rather than chronological age alone?

Which conserved mediators carry survival versus tissue-function effects, and can adult rescue isolate them?

How much of survival benefit reflects cancer delay, demographic hazard changes or broader functional aging?

Can mTORC1-selective regimens preserve benefit while avoiding TORC2, metabolic and immune harm across sexes and backgrounds?

Can independent powered clinical trials show durable functional or disease benefit beyond biomarkers and exploratory subgroups?

Do combination effects remain after exposure matching, complete pathway engagement and shared-cohort accounting?

METHODS AND CONSENSUS CONTRIBUTION

Consensus was used through the signed-in browser for discovery, counterevidence, research-gap and timeline suggestions, and attempted checks of specific indexed full-text passages. Returned Methods/Results passages were reconciled with original-paper passages where available; failed retrievals, source substitutions and unverified aspects are recorded in the case reconciliation. Successful passage checks are distinguished from provider summaries. Provider screening counts, citation counts and meters were not used as primary counts or HSEF scores. This source log records access depth; it does not claim complete-paper or supplement review. The monthly API allowance was conserved: zero Consensus API calls in this batch.

REVIEWER NOTES

59 primary reports examined; four have selected original-body passages examined. The Autophagy research summary PMID39212197 was classified from its body and excluded, replaced by original PMID39117797. Consensus targeted verification failed to retrieve the named originals, so those details are attributed to direct original-body checks rather than Consensus verification. Four public-body requests failed. Linked errata for S6K1, SASP and splicing originals were recorded but their detailed contents were not examined. No full-paper or supplement audit is claimed.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

ADVERSARIAL REVIEW AND APPROVAL

Authoring model: Sol 6.1. Adversarial reviewer: Claude Opus 5.5 (Anthropic). Date: 2026-10-06.

Scope of checks. All 59 reference PMIDs verified against PubMed metadata (title, first author, year, journal, DOI) — 59/59 resolve to the stated record; none carries a retraction or expression of concern. Ten load-bearing claims were spot-checked against the cited abstracts or retained original passages (the three-site late-life ITP rapamycin result; transient middle-age rapamycin and its "up to 60%" life-expectancy figure; the RTB101 phase 2b/phase 3 report and its separate populations and endpoints; the PEARL trial's 114 completers, 11 discontinuations, null visceral-adiposity primary endpoint and secondary female lean-mass signal; everolimus and influenza-vaccination response; the mTOR-hypomorph segmental ageing result; autophagy-dependence experiments). Scoring logic was re-derived from references/hsef-framework.md and SKILL.md Steps 3, 8–12: the index-prescribed primary-subclaim rule is applied to the named gate SC2 (Γ) rather than to the stronger SC1 (Η), and the reported alternatives (weakest-link Γ, scope-matched Γ) are arithmetically correct for this matrix. The exclusion of PMID 39212197 as a research summary is documented and the partial-body count (4) matches the ledger.

Findings. No corrections were required. No factual, citation, scoring or internal-consistency error was demonstrable in this review.

Rejected findings (checked, no change). (a) Eight references carry a print/issue year one later than PubMed's e-publication year (refs 5, 15, 26, 27, 28, 34, 35, 37); the print-year convention is used consistently and is not an error. (b) The headline Γ was tested against the case for lifting it on the strength of SC1: the registered gate is SC2, SKILL.md Step 3 forbids rule-shopping after scoring, and no scope-matched discriminator for central rate-limiting primacy is present in the corpus — Γ stands, with the Η sensitivity reported as required. (c) The retention of a body-retrieval failure for PMID 19587680 does not affect any load-bearing claim, since the ITP result is carried by the abstract-level record.

Residual limitations. Verification depth is abstract/metadata plus the four retained partial bodies; no complete-paper or supplement audit was performed by either model. Human evidence remains short-duration and surrogate-endpoint based, as the review states.

Approval: Following adversarial review and the corrections listed above, the revised document is approved. — Claude Opus 5.5 (Anthropic), 2026-10-06.

REFERENCES

1. Harrison DE, Strong R, Sharp ZD et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009. PMID 19587680. DOI: 10.1038/nature08221. Access: abstract_metadata. Study: ITP heterogeneous-mouse platform.

2. Ferrara-Romeo I, Martinez P, Saraswati S et al. The mTOR pathway is necessary for survival of mice with short telomeres. Nature communications. 2020. PMID 32127537. DOI: 10.1038/s41467-020-14962-1. Access: abstract_metadata. Study: PMID32127537.

3. Laberge RM, Sun Y, Orjalo AV et al. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nature cell biology. 2015. PMID 26147250. DOI: 10.1038/ncb3195. Access: abstract_metadata. Study: PMID26147250.

4. Ham DJ, Börsch A, Lin S et al. The neuromuscular junction is a focal point of mTORC1 signaling in sarcopenia. Nature communications. 2020. PMID 32908143. DOI: 10.1038/s41467-020-18140-1. Access: abstract_metadata. Study: PMID32908143.

5. Baar EL, Carbajal KA, Ong IM et al. Sex- and tissue-specific changes in mTOR signaling with age in C57BL/6J mice. Aging cell. 2016. PMID 26695882. DOI: 10.1111/acel.12425. Access: abstract_metadata. Study: PMID26695882.

6. Ramalingam P, Poulos MG, Gutkin MC et al. Endothelial mTOR maintains hematopoiesis during aging. The Journal of experimental medicine. 2020. PMID 32289154. DOI: 10.1084/jem.20191212. Access: abstract_metadata. Study: PMID32289154.

7. Flynn JM, O'Leary MN, Zambataro CA et al. Late-life rapamycin treatment reverses age-related heart dysfunction. Aging cell. 2013. PMID 23734717. DOI: 10.1111/acel.12109. Access: abstract_metadata. Study: Old-heart rapamycin program.

8. Castillo-Quan JI, Tain LS, Kinghorn KJ et al. A triple drug combination targeting components of the nutrient-sensing network maximizes longevity. Proceedings of the National Academy of Sciences of the United States of America. 2019. PMID 31570569. DOI: 10.1073/pnas.1913212116. Access: abstract_metadata. Study: PMID31570569.

9. Shen Z, Hinson A, Miller RA et al. Cap-independent translation: A shared mechanism for lifespan extension by rapamycin, acarbose, and 17α-estradiol. Aging cell. 2021. PMID 33742521. DOI: 10.1111/acel.13345. Access: abstract_metadata. Study: PMID33742521.

10. Chiao YA, Kolwicz SC, Basisty N et al. Rapamycin transiently induces mitochondrial remodeling to reprogram energy metabolism in old hearts. Aging. 2016. PMID 26872208. DOI: 10.18632/aging.100881. Access: abstract_metadata. Study: Old-heart rapamycin program.

11. Chung CL, Lawrence I, Hoffman M et al. Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial. GeroScience. 2019. PMID 31761958. DOI: 10.1007/s11357-019-00113-y. Access: abstract_metadata. Study: PMID31761958.

12. Zaseck LW, Miller RA, Brooks SV et al. Rapamycin Attenuates Age-associated Changes in Tibialis Anterior Tendon Viscoelastic Properties. The journals of gerontology. Series A, Biological sciences and medical sciences. 2016. PMID 26809496. DOI: 10.1093/gerona/glv307. Access: abstract_metadata. Study: PMID26809496.

13. Shavlakadze T, Zhu J, Wang S et al. Short-term Low-Dose mTORC1 Inhibition in Aged Rats Counter-Regulates Age-Related Gene Changes and Blocks Age-Related Kidney Pathology. The journals of gerontology. Series A, Biological sciences and medical sciences. 2018. PMID 29304191. DOI: 10.1093/gerona/glx249. Access: abstract_metadata. Study: PMID29304191.

14. Moel M, Harinath G, Lee V et al. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging. 2025. PMID 40188830. DOI: 10.18632/aging.206235. Access: full_text_partial. Study: PMID40188830.

15. Yang SB, Lee HY, Young DM et al. Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity. Journal of molecular medicine (Berlin, Germany). 2012. PMID 22105852. DOI: 10.1007/s00109-011-0834-3. Access: abstract_metadata. Study: PMID22105852.

16. Xu C, Yu C, Zhang J et al. YTHDF1 differentiates the contributing roles of mTORC1 in aging. Molecular cell. 2025. PMID 40441158. DOI: 10.1016/j.molcel.2025.05.003. Access: abstract_metadata. Study: PMID40441158.

17. Mannick JB, Del Giudice G, Lattanzi M et al. mTOR inhibition improves immune function in the elderly. Science translational medicine. 2014. PMID 25540326. DOI: 10.1126/scitranslmed.3009892. Access: abstract_metadata. Study: PMID25540326.

18. Green CL, Trautman ME, Chaiyakul K et al. Dietary restriction of isoleucine increases healthspan and lifespan of genetically heterogeneous mice. Cell metabolism. 2023. PMID 37939658. DOI: 10.1016/j.cmet.2023.10.005. Access: abstract_metadata. Study: PMID37939658.

19. Admasu TD, Chaithanya Batchu K, Barardo D et al. Drug Synergy Slows Aging and Improves Healthspan through IGF and SREBP Lipid Signaling. Developmental cell. 2018. PMID 30269951. DOI: 10.1016/j.devcel.2018.09.001. Access: abstract_metadata. Study: PMID30269951.

20. Soukas AA, Kane EA, Carr CE et al. Rictor/TORC2 regulates fat metabolism, feeding, growth, and life span in Caenorhabditis elegans. Genes & development. 2009. PMID 19240135. DOI: 10.1101/gad.1775409. Access: abstract_metadata. Study: PMID19240135.

21. Su Y, Wang T, Wu N et al. Alpha-ketoglutarate extends Drosophila lifespan by inhibiting mTOR and activating AMPK. Aging. 2019. PMID 31242135. DOI: 10.18632/aging.102045. Access: abstract_metadata. Study: PMID31242135.

22. Shi X, Endicott SJ, Miller RA et al. Regulation of mTOR complexes in long-lived growth hormone receptor knockout and Snell dwarf mice. Aging. 2022. PMID 35305083. DOI: 10.18632/aging.203959. Access: abstract_metadata. Study: PMID35305083.

23. Fang Y, Hill CM, Darcy J et al. Effects of rapamycin on growth hormone receptor knockout mice. Proceedings of the National Academy of Sciences of the United States of America. 2018. PMID 29378959. DOI: 10.1073/pnas.1717065115. Access: abstract_metadata. Study: PMID29378959.

24. Wilkinson JE, Burmeister L, Brooks SV et al. Rapamycin slows aging in mice. Aging cell. 2012. PMID 22587563. DOI: 10.1111/j.1474-9726.2012.00832.x. Access: abstract_metadata. Study: PMID22587563.

25. Arriola Apelo SI, Lin A, Brinkman JA et al. Ovariectomy uncouples lifespan from metabolic health and reveals a sex-hormone-dependent role of hepatic mTORC2 in aging. eLife. 2020. PMID 32720643. DOI: 10.7554/eLife.56177. Access: abstract_metadata. Study: PMID32720643.

26. Chang K, Kang P, Liu Y et al. TGFB-INHB/activin signaling regulates age-dependent autophagy and cardiac health through inhibition of MTORC2. Autophagy. 2020. PMID 31884871. DOI: 10.1080/15548627.2019.1704117. Access: abstract_metadata. Study: PMID31884871.

27. Fok WC, Zhang Y, Salmon AB et al. Short-term treatment with rapamycin and dietary restriction have overlapping and distinctive effects in young mice. The journals of gerontology. Series A, Biological sciences and medical sciences. 2013. PMID 22570137. DOI: 10.1093/gerona/gls127. Access: abstract_metadata. Study: PMID22570137.

28. Zhang Y, Bokov A, Gelfond J et al. Rapamycin extends life and health in C57BL/6 mice. The journals of gerontology. Series A, Biological sciences and medical sciences. 2014. PMID 23682161. DOI: 10.1093/gerona/glt056. Access: abstract_metadata. Study: PMID23682161.

29. Fang Y, Westbrook R, Hill C et al. Duration of rapamycin treatment has differential effects on metabolism in mice. Cell metabolism. 2013. PMID 23473038. DOI: 10.1016/j.cmet.2013.02.008. Access: abstract_metadata. Study: PMID23473038.

30. McQuary PR, Liao CY, Chang JT et al. C. elegans S6K Mutants Require a Creatine-Kinase-like Effector for Lifespan Extension. Cell reports. 2016. PMID 26923601. DOI: 10.1016/j.celrep.2016.02.012. Access: abstract_metadata. Study: PMID26923601.

31. Miller RA, Harrison DE, Astle CM et al. Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging cell. 2014. PMID 24341993. DOI: 10.1111/acel.12194. Access: full_text_partial. Study: ITP dose cohort, shared platform.

32. An JY, Kerns KA, Ouellette A et al. Rapamycin rejuvenates oral health in aging mice. eLife. 2020. PMID 32342860. DOI: 10.7554/eLife.54318. Access: abstract_metadata. Study: PMID32342860.

33. Drake JC, Peelor FF, Biela LM et al. Assessment of mitochondrial biogenesis and mTORC1 signaling during chronic rapamycin feeding in male and female mice. The journals of gerontology. Series A, Biological sciences and medical sciences. 2013. PMID 23657975. DOI: 10.1093/gerona/glt047. Access: abstract_metadata. Study: PMID23657975.

34. Quarles E, Basisty N, Chiao YA et al. Rapamycin persistently improves cardiac function in aged, male and female mice, even following cessation of treatment. Aging cell. 2020. PMID 31823466. DOI: 10.1111/acel.13086. Access: abstract_metadata. Study: Old-heart persistence program.

35. Lind MI, Zwoinska MK, Meurling S et al. Sex-specific Tradeoffs With Growth and Fitness Following Life-span Extension by Rapamycin in an Outcrossing Nematode, Caenorhabditis remanei. The journals of gerontology. Series A, Biological sciences and medical sciences. 2016. PMID 26472877. DOI: 10.1093/gerona/glv174. Access: abstract_metadata. Study: PMID26472877.

36. Martínez-Cisuelo V, Gómez J, García-Junceda I et al. Rapamycin reverses age-related increases in mitochondrial ROS production at complex I, oxidative stress, accumulation of mtDNA fragments inside nuclear DNA, and lipofuscin level, and increases autophagy, in the liver of middle-aged mice. Experimental gerontology. 2016. PMID 27498120. DOI: 10.1016/j.exger.2016.08.002. Access: abstract_metadata. Study: PMID27498120.

37. Heintz C, Doktor TK, Lanjuin A et al. Splicing factor 1 modulates dietary restriction and TORC1 pathway longevity in C. elegans. Nature. 2017. PMID 27919065. DOI: 10.1038/nature20789. Access: abstract_metadata. Study: PMID27919065.

38. Leontieva OV, Paszkiewicz GM, Blagosklonny MV et al. Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet. Aging cell. 2014. PMID 24655348. DOI: 10.1111/acel.12211. Access: abstract_metadata. Study: PMID24655348.

39. Richardson NE, Konon EN, Schuster HS et al. Lifelong restriction of dietary branched-chain amino acids has sex-specific benefits for frailty and lifespan in mice. Nature aging. 2021. PMID 33796866. DOI: 10.1038/s43587-020-00006-2. Access: abstract_metadata. Study: PMID33796866.

40. Comas M, Toshkov I, Kuropatwinski KK et al. New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-/- mice by delaying carcinogenesis. Aging. 2012. PMID 23117593. DOI: 10.18632/aging.100496. Access: abstract_metadata. Study: PMID23117593.

41. Leontieva OV, Blagosklonny MV et al. DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence. Aging. 2010. PMID 21212465. DOI: 10.18632/aging.100265. Access: abstract_metadata. Study: PMID21212465.

42. Strong R, Miller RA, Bogue M et al. Rapamycin-mediated mouse lifespan extension: Late-life dosage regimes with sex-specific effects. Aging cell. 2020. PMID 33145977. DOI: 10.1111/acel.13269. Access: abstract_metadata. Study: ITP late-life cohort, shared platform.

43. Stockklausner C, Raffel S, Klermund J et al. A novel autosomal recessive TERT T1129P mutation in a dyskeratosis congenita family leads to cellular senescence and loss of CD34+ hematopoietic stem cells not reversible by mTOR-inhibition. Aging. 2015. PMID 26546739. DOI: 10.18632/aging.100835. Access: abstract_metadata. Study: PMID26546739.

44. Tóth ML, Sigmond T, Borsos E et al. Longevity pathways converge on autophagy genes to regulate life span in Caenorhabditis elegans. Autophagy. 2008. PMID 18219227. DOI: 10.4161/auto.5618. Access: abstract_metadata. Study: PMID18219227.

45. Kaeberlein M, Powers RW, Steffen KK et al. Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. Science (New York, N.Y.). 2005. PMID 16293764. DOI: 10.1126/science.1115535. Access: abstract_metadata. Study: PMID16293764.

46. Kapahi P, Zid BM, Harper T et al. Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Current biology : CB. 2004. PMID 15186745. DOI: 10.1016/j.cub.2004.03.059. Access: abstract_metadata. Study: PMID15186745.

47. Selman C, Tullet JM, Wieser D et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science (New York, N.Y.). 2009. PMID 19797661. DOI: 10.1126/science.1177221. Access: abstract_metadata. Study: S6K1 mutant platform.

48. Selman C, Sinclair A, Pedroni SM et al. Evidence that hematopoietic stem cell function is preserved during aging in long-lived S6K1 mutant mice. Oncotarget. 2016. PMID 27083004. DOI: 10.18632/oncotarget.8729. Access: abstract_metadata. Study: S6K1 mutant platform follow-up.

49. Mannick JB, Teo G, Bernardo P et al. Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials. The lancet. Healthy longevity. 2021. PMID 33977284. DOI: 10.1016/S2666-7568(21)00062-3. Access: full_text_partial. Study: Distinct phase2b and phase3 trial cohorts.

50. Bitto A, Ito TK, Pineda VV et al. Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice. eLife. 2016. PMID 27549339. DOI: 10.7554/eLife.16351. Access: abstract_metadata. Study: PMID27549339.

51. Neff F, Flores-Dominguez D, Ryan DP et al. Rapamycin extends murine lifespan but has limited effects on aging. The Journal of clinical investigation. 2013. PMID 23863708. DOI: 10.1172/JCI67674. Access: abstract_metadata. Study: PMID23863708.

52. Schreiber KH, Arriola Apelo SI, Yu D et al. A novel rapamycin analog is highly selective for mTORC1 in vivo. Nature communications. 2019. PMID 31324799. DOI: 10.1038/s41467-019-11174-0. Access: abstract_metadata. Study: PMID31324799.

53. Gkioni L, Nespital T, Baghdadi M et al. The geroprotectors trametinib and rapamycin combine additively to extend mouse healthspan and lifespan. Nature aging. 2025. PMID 40437307. DOI: 10.1038/s43587-025-00876-4. Access: full_text_partial. Study: Hybrid mouse combination cohorts; some liver pathology previously published.

54. Mannick JB, Morris M, Hockey HP et al. TORC1 inhibition enhances immune function and reduces infections in the elderly. Science translational medicine. 2018. PMID 29997249. DOI: 10.1126/scitranslmed.aaq1564. Access: abstract_metadata. Study: PMID29997249.

55. Wu JJ, Liu J, Chen EB et al. Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression. Cell reports. 2013. PMID 23994476. DOI: 10.1016/j.celrep.2013.07.030. Access: abstract_metadata. Study: PMID23994476.

56. Urfer SR, Kaeberlein TL, Mailheau S et al. A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs. GeroScience. 2017. PMID 28374166. DOI: 10.1007/s11357-017-9972-z. Access: abstract_metadata. Study: PMID28374166.

57. Bjedov I, Toivonen JM, Kerr F et al. Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. Cell metabolism. 2010. PMID 20074526. DOI: 10.1016/j.cmet.2009.11.010. Access: abstract_metadata. Study: PMID20074526.

58. Kraig E, Linehan LA, Liang H et al. A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects. Experimental gerontology. 2018. PMID 29408453. DOI: 10.1016/j.exger.2017.12.026. Access: abstract_metadata. Study: PMID29408453.

59. Hofer SJ, Daskalaki I, Bergmann M et al. Spermidine is essential for fasting-mediated autophagy and longevity. Nature cell biology. 2024. PMID 39117797. DOI: 10.1038/s41556-024-01468-x. Access: abstract_metadata. Study: PMID39117797.

Source-specific evidence cards

[1] Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.

Shows: Late-life rapamycin extends survival at three sites

Does not show: Does not isolate aging rate from disease delay or prove primacy

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[2] The mTOR pathway is necessary for survival of mice with short telomeres.

Shows: Rapamycin and S6K loss shorten survival in Terc-null context

Does not show: Does not negate normal mouse benefit

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[3] MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation.

Shows: IL1A translation mediates a defined SASP effect with rescue

Does not show: Does not establish organismal aging mediation; linked erratum unexamined

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. ErratumIn: PMID33824512. Subclaims: SC2.

[4] The neuromuscular junction is a focal point of mTORC1 signaling in sarcopenia.

Shows: Muscle mTORC1 activation and inhibition alter sarcopenic phenotypes

Does not show: Does not establish all-organ rate limitation

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[5] Sex- and tissue-specific changes in mTOR signaling with age in C57BL/6J mice.

Shows: Age-related signaling is heterogeneous rather than uniformly elevated

Does not show: Does not exclude transient or cell-specific hyperactivation

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[6] Endothelial mTOR maintains hematopoiesis during aging.

Shows: Reduced endothelial mTOR disrupts aged hematopoietic support

Does not show: Does not generalize all tissues

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[7] Late-life rapamycin treatment reverses age-related heart dysfunction.

Shows: Late short rapamycin improves cardiac function

Does not show: Does not demonstrate whole-life or human benefit

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[8] A triple drug combination targeting components of the nutrient-sensing network maximizes longevity.

Shows: Multiple pathway drugs combine for lifespan benefit

Does not show: Does not prove complete pathway independence

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[9] Cap-independent translation: A shared mechanism for lifespan extension by rapamycin, acarbose, and 17α-estradiol.

Shows: Translation programs track geroprotective manipulations

Does not show: Does not test organismal lifespan mediation in this report

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[10] Rapamycin transiently induces mitochondrial remodeling to reprogram energy metabolism in old hearts.

Shows: Autophagy and energetics change with distinct timing during functional benefit

Does not show: Does not isolate one necessary universal mediator

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[11] Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial.

Shows: Local skin markers and appearance improve with large attrition

Does not show: Does not establish systemic human healthspan

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[12] Rapamycin Attenuates Age-associated Changes in Tibialis Anterior Tendon Viscoelastic Properties.

Shows: Rapamycin preserves selected aged tendon mechanics

Does not show: Does not show all functional domains

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[13] Short-term Low-Dose mTORC1 Inhibition in Aged Rats Counter-Regulates Age-Related Gene Changes and Blocks Age-Related Kidney Pathology.

Shows: RAD001 affects selected renal and other tissue pathology

Does not show: Does not establish lifespan or centrality

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[14] Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results.

Shows: Primary visceral-fat endpoint is null; selected secondary female lean-mass signal

Does not show: Completer analysis and broad exploratory outcomes do not prove human healthy-life extension

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 1:RESULTS, 3:METHODS. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[15] Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity.

Shows: Rapamycin impairs glucose handling and islet measures

Does not show: Does not negate survival benefit or establish all dosing schedules harmful

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[16] YTHDF1 differentiates the contributing roles of mTORC1 in aging.

Shows: Cholesterol-axis mTORC1 activation contributes to engineered aging phenotypes

Does not show: Rescue of an engineered lesion is not proof of normal-aging primacy

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[17] mTOR inhibition improves immune function in the elderly.

Shows: Low-dose everolimus improves vaccination response

Does not show: Does not measure healthy lifespan

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[18] Dietary restriction of isoleucine increases healthspan and lifespan of genetically heterogeneous mice.

Shows: Isoleucine restriction improves frailty and survival with sex dependence

Does not show: Diet has multiple mediators; no exclusive mTOR mechanism

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[19] Drug Synergy Slows Aging and Improves Healthspan through IGF and SREBP Lipid Signaling.

Shows: Drug combinations engage distinct network and lipid mechanisms

Does not show: Does not establish human benefit or independent pathways in mammals

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[20] Rictor/TORC2 regulates fat metabolism, feeding, growth, and life span in Caenorhabditis elegans.

Shows: TORC2 survival effects reverse with food context and intake

Does not show: Does not imply universal TORC2 inhibition benefit

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[21] Alpha-ketoglutarate extends Drosophila lifespan by inhibiting mTOR and activating AMPK.

Shows: AKG lifespan and metabolism change alongside AMPK and TOR signals

Does not show: Marker changes do not isolate mTOR mediation

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[22] Regulation of mTOR complexes in long-lived growth hormone receptor knockout and Snell dwarf mice.

Shows: TSC modulation links GH mutants to reduced mTORC1 signaling

Does not show: Does not test survival necessity in this report

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[23] Effects of rapamycin on growth hormone receptor knockout mice.

Shows: Rapamycin extends control life but shortens GHRKO life with mTORC2 suppression

Does not show: Context boundary does not negate normal-aging rapamycin effects

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[24] Rapamycin slows aging in mice.

Shows: Multiple age-sensitive phenotypes improve while cataract and testis harms rise

Does not show: Does not establish uniform aging-rate suppression

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[25] Ovariectomy uncouples lifespan from metabolic health and reveals a sex-hormone-dependent role of hepatic mTORC2 in aging.

Shows: Sex hormone and tissue perturbations uncouple metabolic health from survival

Does not show: Does not establish universal effects outside mapped contexts

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[26] TGFB-INHB/activin signaling regulates age-dependent autophagy and cardiac health through inhibition of MTORC2.

Shows: Cardiac TORC2 activation improves autophagy function and survival

Does not show: Does not resolve all organismal TORC2 effects

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[27] Short-term treatment with rapamycin and dietary restriction have overlapping and distinctive effects in young mice.

Shows: Diet and rapamycin share TOR suppression yet differ physiologically

Does not show: Does not quantify distinct lifespan mediators

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[28] Rapamycin extends life and health in C57BL/6 mice.

Shows: Late rapamycin improves survival and selected functions

Does not show: Many metabolic and activity measures do not change

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[29] Duration of rapamycin treatment has differential effects on metabolism in mice.

Shows: Metabolic effects vary with treatment duration

Does not show: Does not directly establish survival mediation

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[30] C. elegans S6K Mutants Require a Creatine-Kinase-like Effector for Lifespan Extension.

Shows: ARGK1 is a defined effector of S6K longevity with AMPK link

Does not show: Does not show a universal mammalian mediator

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[31] Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction.

Shows: Dose and sex gradients replicate survival effects

Does not show: Gompertz slope estimates do not prove slowed demographic aging rate

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph0, 1:Results:paragraph2, 1:Results:paragraph3, 1:Results:paragraph4, 1:Results:paragraph5, 1:Results:paragraph6. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[32] Rapamycin rejuvenates oral health in aging mice.

Shows: Short rapamycin improves bone inflammation and microbiome measures

Does not show: Does not demonstrate systemic lifespan mediation

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[33] Assessment of mitochondrial biogenesis and mTORC1 signaling during chronic rapamycin feeding in male and female mice.

Shows: TOR and synthesis responses differ by tissue and sex

Does not show: Does not test lifespan mediation

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[34] Rapamycin persistently improves cardiac function in aged, male and female mice, even following cessation of treatment.

Shows: Functional benefits persist after drug withdrawal

Does not show: Does not establish whole-body or human persistence

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[35] Sex-specific Tradeoffs With Growth and Fitness Following Life-span Extension by Rapamycin in an Outcrossing Nematode, Caenorhabditis remanei.

Shows: Lifespan growth and fitness tradeoffs depend on sex and exposure timing

Does not show: Does not generalize all ages or species

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[36] Rapamycin reverses age-related increases in mitochondrial ROS production at complex I, oxidative stress, accumulation of mtDNA fragments inside nuclear DNA, and lipofuscin level, and increases autophagy, in the liver of middle-aged mice.

Shows: Rapamycin reduces ROS and damage markers with autophagy changes

Does not show: Does not show damage reduction mediates survival

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[37] Splicing factor 1 modulates dietary restriction and TORC1 pathway longevity in C. elegans.

Shows: SFA1 is required for selected TOR and diet longevity effects

Does not show: Not a universal mediator; linked erratum content unexamined

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. ErratumIn: PMID28700577. Subclaims: SC1, SC2.

[38] Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet.

Shows: Weekly rapamycin improves survival to planned sacrifice

Does not show: Disease context and censored follow-up are not natural maximum lifespan

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[39] Lifelong restriction of dietary branched-chain amino acids has sex-specific benefits for frailty and lifespan in mice.

Shows: BCAA restriction has sex-specific survival and frailty effects

Does not show: Does not isolate mTOR as dominant diet mediator

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[40] New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-/- mice by delaying carcinogenesis.

Shows: Rapatar delays cancer and increases survival

Does not show: Does not distinguish general aging from engineered cancer rescue

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[41] DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence.

Shows: mTOR reactivation influences senescence in arrested cells

Does not show: In vitro geroconversion is not organismal aging primacy

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[42] Rapamycin-mediated mouse lifespan extension: Late-life dosage regimes with sex-specific effects.

Shows: Late dose and intermittent regimens affect survival by sex

Does not show: Food-source variation complicates comparisons; shared ITP platform

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[43] A novel autosomal recessive TERT T1129P mutation in a dyskeratosis congenita family leads to cellular senescence and loss of CD34+ hematopoietic stem cells not reversible by mTOR-inhibition.

Shows: Rapamycin fails to rescue defective HSC function despite fibroblast benefit

Does not show: Not a normal-aging human trial

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[44] Longevity pathways converge on autophagy genes to regulate life span in Caenorhabditis elegans.

Shows: Autophagy loss blocks selected longevity pathways

Does not show: Shared downstream requirement does not establish mTOR exclusivity

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[45] Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients.

Shows: TOR and Sch9 deletion extend replicative life with dietary epistasis

Does not show: Yeast replicative life is not mammalian healthspan

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[46] Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway.

Shows: Multiple TOR manipulations extend life depending on nutrition

Does not show: Does not establish uniform central rate limitation

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[47] Ribosomal protein S6 kinase 1 signaling regulates mammalian life span.

Shows: Downstream genetic perturbation extends survival and selected functions

Does not show: Developmental and sex boundaries remain; erratum details unexamined

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. ErratumIn: PMIDnot supplied. Subclaims: SC1, SC2.

[48] Evidence that hematopoietic stem cell function is preserved during aging in long-lived S6K1 mutant mice.

Shows: Aged donor HSC engraftment is preserved

Does not show: Shares mutant platform; no independent lifespan replication

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[49] Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials.

Shows: Phase2b pooled single-dose contrast positive after combination null; phase3 primary null despite IFN engagement

Does not show: Endpoint and population changes limit direct comparison and neither trial measures healthy lifespan

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph2, 1:Methods:paragraph4, 1:Methods:paragraph6, 1:Methods:paragraph8, 1:Methods:paragraph9, 1:Methods:paragraph10. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[50] Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice.

Shows: Transient rapamycin changes survival with sex and tumour-spectrum boundaries

Does not show: Up-to-60% life expectancy is not universal full-life extension

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[51] Rapamycin extends murine lifespan but has limited effects on aging.

Shows: Survival improves but few age phenotypes improve; young controls reveal age-independent effects

Does not show: Does not negate other mouse background or function benefits

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[52] A novel rapamycin analog is highly selective for mTORC1 in vivo.

Shows: DL001 separates mTORC1 inhibition from several metabolic side effects

Does not show: Does not report lifespan benefit

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[53] The geroprotectors trametinib and rapamycin combine additively to extend mouse healthspan and lifespan.

Shows: MEK inhibition adds survival benefit to intermittent rapamycin with separate engagement

Does not show: Additivity does not prove perfect independence or preclude shared network centrality

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph0, 1:Results:paragraph4, 1:Results:paragraph5, 1:Results:paragraph7, 1:Results:paragraph8, 1:Results:paragraph12, 1:Results:paragraph14, 1:Results:paragraph15. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[54] TORC1 inhibition enhances immune function and reduces infections in the elderly.

Shows: Low-dose TORC1 combination reduces reported infections and improves immune endpoints

Does not show: Does not establish general healthy-life extension

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[55] Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression.

Shows: Genetic reduction extends survival with segmental functional preservation

Does not show: Developmental manipulation and uneven organ effects do not prove central primacy

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[56] A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs.

Shows: Short low-dose rapamycin suggests selected cardiac effects

Does not show: Small short trial does not test lifespan

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[57] Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster.

Shows: Rapamycin longevity requires defined autophagy and translation pathways

Does not show: Does not establish the same mediator across mammals

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[58] A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects.

Shows: Short treatment leaves measured cognition performance and perceived health unchanged

Does not show: Small safety pilot cannot exclude longer-term efficacy; enrollment wording requires body verification

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[59] Spermidine is essential for fasting-mediated autophagy and longevity.

Shows: Polyamine and hypusination perturbation tests selected fasting longevity mechanisms

Does not show: Human fasting markers are not human lifespan mediation; not exclusive mTOR proof

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

Documentary record

Every grade on this site is reproducible from its record. The files below are the posted edition exactly as assessed.

• SHA256.txt
• codex-correction-provenance.json
• consensus-addendum.md
• consensus-validation.json
• edition-approval-audit.json
• mtor-central-aging-driver.review.md
• mtor-central-aging-driver.scorecard.json
• validation-report.json
• validation-round2-2026-10-14.json
• validation.txt

Sources: 59 · load-bearing claims: 62 · verified: 62 · unverified: 0 · contradicted: 0 · schema 5.3